ST-elevation myocardial infarction

Summary

ST-elevation myocardial infarction (MONDO:0041656) is a disease and 481 clinical trials. Top therapeutic interventions include ticagrelor, cangrelor, and prasugrel. A subtype of acute myocardial infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 481

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ST-elevation myocardial infarction
Mondo ID	MONDO:0041656
MeSH	D000072657
SNOMED CT	401303003
Is cancer (heuristic)	no

Also known as: acute-ST segment elevation myocardial infarction · ST segment elevation myocardial infarction · STEMI

Disease family

This is a subtype of acute myocardial infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › acute myocardial infarction › ST-elevation myocardial infarction

Related subtypes (5): acute subendocardial myocardial infarction, acute inferoposterior infarction, acute inferolateral myocardial infarction, acute anterolateral myocardial infarction, strictly posterior acute myocardial infarction

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 20 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Reteplase	Approved (phase 4)
Abciximab	Phase 3 (in late-stage trials)
Aspirin	Phase 3 (in late-stage trials)
Atorvastatin	Phase 3 (in late-stage trials)
Clopidogrel	Phase 3 (in late-stage trials)
Colchicine	Phase 3 (in late-stage trials)
Dapagliflozin	Phase 3 (in late-stage trials)
Dutogliptin	Phase 3 (in late-stage trials)
Enalapril	Phase 3 (in late-stage trials)
Enoxaparin Sodium	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Heparin	Phase 3 (in late-stage trials)
Levosimendan	Phase 3 (in late-stage trials)
Metoprolol	Phase 3 (in late-stage trials)
Prasugrel	Phase 3 (in late-stage trials)
Sacubitril	Phase 3 (in late-stage trials)
Spironolactone	Phase 3 (in late-stage trials)
Tenecteplase	Phase 3 (in late-stage trials)
Ticagrelor	Phase 3 (in late-stage trials)
Valsartan	Phase 3 (in late-stage trials)
Zalunfiban	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetylcysteine, Adenosine, Cangrelor, Danegaptide, Empagliflozin, Epoetin Alfa, Eptifibatide, Evolocumab, Nitric Oxide, Roxadustat, Sodium Chloride, Sodium Iodide, Thymosin, Urokinase.

Clinical trials & evidence

Clinical trials

Clinical trials: 481.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	314
PHASE4	62
PHASE3	54
PHASE2	38
PHASE2/PHASE3	7
PHASE1/PHASE2	4
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03646357	PHASE4	ACTIVE_NOT_RECRUITING	BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
NCT03778554	PHASE4	ACTIVE_NOT_RECRUITING	Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
NCT05410925	PHASE4	RECRUITING	Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT06756945	PHASE4	NOT_YET_RECRUITING	Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial
NCT07195812	PHASE4	NOT_YET_RECRUITING	Rivaroxaban for Slow Coronary Flow After PCI in STEMI
NCT00962416	PHASE4	COMPLETED	Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)
NCT01033058	PHASE4	UNKNOWN	Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI
NCT01158846	PHASE4	UNKNOWN	Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
NCT01203982	PHASE4	COMPLETED	Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)
NCT01281033	PHASE4	COMPLETED	CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial
NCT01382472	PHASE4	COMPLETED	Microcirculation In Acute Coronary Syndromes
NCT01384019	PHASE4	COMPLETED	Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)
NCT01385631	PHASE4	COMPLETED	Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.
NCT01423929	PHASE4	COMPLETED	Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion
NCT01499407	PHASE4	UNKNOWN	Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction
NCT01510171	PHASE4	COMPLETED	Rapid Activity of Platelet Inhibitor Drugs Study
NCT01519518	PHASE4	COMPLETED	How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
NCT01575795	PHASE4	COMPLETED	Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
NCT01761786	PHASE4	COMPLETED	Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
NCT01826552	PHASE4	COMPLETED	Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
NCT01930682	PHASE4	COMPLETED	EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction
NCT01950416	PHASE4	COMPLETED	Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
NCT02026219	PHASE4	COMPLETED	Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
NCT02032290	PHASE4	UNKNOWN	Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
NCT02032303	PHASE4	UNKNOWN	Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
NCT02046486	PHASE4	COMPLETED	OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)
NCT02048085	PHASE4	WITHDRAWN	Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
NCT02123004	PHASE4	UNKNOWN	Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
NCT02217878	PHASE4	COMPLETED	Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
NCT02224534	PHASE4	UNKNOWN	Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
NCT02311231	PHASE4	COMPLETED	Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
NCT02592694	PHASE4	UNKNOWN	Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty
NCT02601781	PHASE4	UNKNOWN	Use of BVS in ST-segment Elevation Myocardial Infarction (STEMI): the BVS STEMI STRATEGY-IT Prospective Registry
NCT02606435	PHASE4	UNKNOWN	Thrombus Aspiration in Patients With STEMI
NCT02723981	PHASE4	WITHDRAWN	COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
NCT02725099	PHASE4	COMPLETED	Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients
NCT02835534	PHASE4	COMPLETED	The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
NCT02913469	PHASE4	UNKNOWN	Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction
NCT02942550	PHASE4	COMPLETED	Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
NCT02943369	PHASE4	COMPLETED	Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TICAGRELOR	4	10
CANGRELOR	4	9
PRASUGREL	4	8
ATORVASTATIN	4	7
TIROFIBAN	4	7
BISOPROLOL	4	6
BIVALIRUDIN	4	5
EVOLOCUMAB	4	5
ABCIXIMAB	4	4
COLCHICINE	4	4
ROSUVASTATIN	4	4
ALTEPLASE	4	3
CLOPIDOGREL	4	3
HEPARIN	4	3
MORPHINE	4	3
OSELTAMIVIR	4	3
OXYGEN	4	3
PYRIDOXINE	4	3
TENECTEPLASE	4	3
ALIROCUMAB	4	2
ALPROSTADIL	4	2
BEMPEDOIC ACID	4	2
METOPROLOL SUCCINATE	4	2
NICORANDIL	4	2
NITROGLYCERIN	4	2
NITROUS ACID	4	2
RIVAROXABAN	4	2
SODIUM IODIDE	4	2
SODIUM NITROPRUSSIDE	4	2
ADENOSINE	4	1